https://www.horizon-labs.co/resources/anthropic
The biotechnology sector has emerged as a dominant force in the 2026 US IPO market, surpassing AI-related listings in terms of performance returns. With a 55% weighted average gain, biotech IPOs are outperforming the broader market, which has seen a 4.4% loss. This trend is overshadowing AI firms, including Anthropic and OpenAI, which have been highly anticipated in the IPO pipeline. Despite the current dominance of biotech in realized returns, AI companies still hold the largest pending IPOs with significant valuations.
The focus on biotechnology IPOs may be influencing market sentiments surrounding AI-related IPOs, particularly those of Anthropic. The market for Anthropic’s IPO by September 30, 2026, currently shows a 5.5% likelihood of a YES outcome. This is a slight decrease from previous days, suggesting that investor attention might be diverted towards the biotech sector, which has shown robust growth and returns.
Anthropic’s IPO market appears to be adjusting to the competitive landscape, where biotechnology firms have set a high-performance benchmark. As the biotech sector continues to capture investor interest, the anticipation and optimism surrounding AI IPOs, including Anthropic’s, could face challenges in maintaining momentum.
